Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction. A VALIANT Study (Valsartan in acute myocardial infarction)

JACC: Heart Failure

Volumn 2, Issue 2, 2014, Pages 159-165

  Lewis, Eldrin F ^a   Li, Yanhong ^b   Pfeffer, Marc A ^a   Solomon, Scott D ^a   Weinfurt, Kevin P ^b   Velazquez, Eric J ^b   Califf, Robert M ^b   Rouleau, Jean Lucien ^c   Kober, Lars ^d   White, Harvey D ^e   Schulman, Kevin A ^b   Reed, Shelby D ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MONTREAL HEART INSTITUTE   (Canada)

^d University of Copenhagen   (Denmark)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Heart failure; Myocardial infarction; Quality of life; Utility

Indexed keywords

VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TETRAZOLE DERIVATIVE; VALINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; EQ 5D; FEMALE; FOLLOW UP; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NONFATAL CARDIOVASCULAR DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SUDDEN CARDIAC DEATH; VISUAL ANALOG SCALE; EQ 5D QUESTIONNAIRE; HEALTH STATUS; HEART EJECTION FRACTION; HEART INFARCTION; SURVIVAL; ACUTE DISEASE; ANALOGS AND DERIVATIVES; BUNDLE-BRANCH BLOCK; CLINICAL TRIAL; DEATH, SUDDEN, CARDIAC; DRUG COMBINATION; HEART FAILURE; HOSPITALIZATION; MULTICENTER STUDY; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA; STROKE; SURVIVOR; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BUNDLE-BRANCH BLOCK; CAPTOPRIL; DEATH, SUDDEN, CARDIAC; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MYOCARDIAL INFARCTION; QUALITY OF LIFE; RECURRENCE; STROKE; SURVIVORS; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 84897500948     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2013.12.003     Document Type: Article

References (28)

1. Guidry U.C., Evans J.C., Larson M.G., Wilson P.W., Murabito J.M., Levy D. Temporal trends in event rates after Q-wave myocardial infarction: the Framingham Heart Study. Circulation 1999, 100:2054-2059.
2. Janardhanan R., Kenchaiah S., Velazquez E.J., et al. Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. Am Heart J 2006, 152:183-189.
3. Sampson U.K., Pfeffer M.A., McMurray J.J., Lokhnygina Y., White H.D., Solomon S.D. Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial. Eur Heart J 2007, 28:685-691.
4. Solomon S.D., Zelenkofske S., McMurray J.J., et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. NEngl J Med 2005, 352:2581-2588.
5. Rumsfeld J.S., Magid D.J., Plomondon M.E., et al. History of depression, angina, and quality of life after acute coronary syndromes. Am Heart J 2003, 145:493-499.
6. Singh M., Rihal C.S., Lennon R.J., Spertus J.A., Nair K.S., Roger V.L. Influence of frailty and health status on outcomes in patients with coronary disease undergoing percutaneous revascularization. Circ Cardiovasc Qual Outcomes 2011, 4:496-502.
7. Heidenreich P.A., Spertus J.A., Jones P.G., et al. Health status identifies heart failure outpatients at risk for hospitalization or death. JAm Coll Cardiol 2006, 47:752-756.
8. Brink E., Grankvist G., Karlson B.W., Hallberg L.R. Health-related quality of life in women and men one year after acute myocardial infarction. Qual Life Res 2005, 14:749-757.
9. Failde I.I., Soto M.M. Changes in health related quality of life 3 months after an acute coronary syndrome. BMC Public Health 2006, 6:18.
10. Kim J., Henderson R.A., Pocock S.J., Clayton T., Sculpher M.J., Fox K.A. Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of Unstable Angina (RITA-3). JAm Coll Cardiol 2005, 45:221-228.
11. Rumsfeld J.S., Magid D.J., Plomondon M.E., et al. Predictors of quality of life following acute coronary syndromes. Am J Cardiol 2001, 88:781-784.
12. Beck C.A., Joseph L., Belisle P., Pilote L. Predictors of quality of life 6 months and 1 year after acute myocardial infarction. Am Heart J 2001, 142:271-279.
13. Aalto A.M., Aro A.R., Weinman J., Heijmans M., Manderbacka K., Elovainio M. Sociodemographic, disease status, and illness perceptions predictors of global self-ratings of health and quality of life among those with coronary heart disease-one year follow-up study. Qual Life Res 2006, 15:1307-1322.
14. Pfeffer M.A., McMurray J., Leizorovicz A., et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000, 140:727-750.
15. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. NEngl J Med 2003, 349:1893-1906.
16. Brazier J., Jones N., Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993, 2:169-180.
17. Nowels D., McGloin J., Westfall J.M., Holcomb S. Validation of the EQ-5D quality of life instrument in patients after myocardial infarction. Qual Life Res Feb 2005, 14:95-105.
18. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208. EuroQol Group.
19. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997, 35:1095-1108.
20. Shaw J.W., Johnson J.A., Coons S.J. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005, 43:203-220.
21. Verbeke G., Molenberghs G. Linear Mixed Models for Longitudinal Data 2000, Springer-Verlag, New York, NY.
22. Rutten-van Molken M.P., Oostenbrink J.B., Tashkin D.P., Burkhart D., Monz B.U. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?. Chest 2006, 130:1117-1128.
23. Eurich D.T., Johnson J.A., Reid K.J., Spertus J.A. Assessing responsiveness of generic and specific health related quality of life measures in heart failure. Health Qual Life Outcomes 2006, 4:89.
24. Lewis E.F., Pfeffer M.A., Feng A., et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol 2011, 6:845-855.
25. Pickard A.S., Wilke C.T., Lin H.W., Lloyd A. Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 2007, 25:365-384.
26. Brown N., Melville M., Gray D., et al. Quality of life four years after acute myocardial infarction: short form 36 scores compared with a normal population. Heart 1999, 81:352-358.
27. Bengtsson I., Hagman M., Wahrborg P., Wedel H. Lasting impact on health-related quality of life after a first myocardial infarction. Int J Cardiol 2004, 97:509-516.
28. Simpson E., Pilote L. Quality of life after acute myocardial infarction: a comparison of diabetic versus non-diabetic acute myocardial infarction patients in Quebec acute care hospitals. Health Qual Life Outcomes 2005, 3:80.